Cancers, Vol. 12, Pages 1871: Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
Cancers, Vol. 12, Pages 1871: Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
Cancers doi: 10.3390/cancers12071871
Authors:
Guillaume Herbreteau
Audrey Vallée
Anne-Chantal Knol
Sandrine Théoleyre
Gaelle Quéreux
Cécile Frénard
Emilie Varey
Paul Hofman
Amir Khammari
Brigitte Dréno
Marc G. Denis
Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of BRAF and NRAS mutations before systemic treatment initiation, was associated with the prognosis of metastatic melanoma. In total, 68 BRAF or NRAS-mutated stage IV or unresectable stage III metastatic cutaneous melanoma patients were included and tested for the presence of BRAF and NRAS mutations in circulating DNA before treatment initiation, using the Cobas BRAF/NRAS Mutation Test (Roche). The expected mutation was detected in the plasma of 34/68 patients (50% sensitivity). ctDNA detection was associated with AJCC stage, along with the number and nature of metastases. ctDNA was less frequently detected in NRAS-mutated than in BRAF-mutated melanoma (36% and 66%, respectively). At initiation of first-line treatment, ctDNA detection was associated with poor prognosis in Progression Free Survival (PFS) and Overall Survival (OS) in univariate analysis (log-rank: p = 0.002 and p < 0.0001, respe...
Source: Cancers - Category: Cancer & Oncology Authors: Guillaume Herbreteau Audrey Vall ée Anne-Chantal Knol Sandrine Th éoleyre Gaelle Qu éreux C écile Frénard Emilie Varey Paul Hofman Amir Khammari Brigitte Dr éno Marc G. Denis Tags: Article Source Type: research